<- Go home

Added to YB: 2024-05-30

Pitch date: 2024-05-15

NTRA [bullish]

Natera, Inc.

+117.36%

current return

Author Info

No bio for this author

Company Info

Natera, Inc., a diagnostics company, provides molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Market Cap

$28.2B

Pitch Price

$106.71

Price Target

N/A

Dividend

N/A

EV/EBITDA

-91.38

P/E

-89.19

EV/Sales

12.92

Sector

Biotechnology

Category

growth

Show full summary:
Parnassus Growth Equity Fund New Position: Natera, Inc.

NTRA: Genetic testing co. in women's health, oncology & organ transplant. Upside from wider test adoption, coverage expansion & new products. Strong mgmt to reach CF breakeven in '23 while balancing growth & profits.

Read full article (1 min)